Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for International Stem Cell (ISCO) over the last 17 years, with Q3 2025 value amounting to $1.0 million.

  • International Stem Cell's Cost of Revenue rose 759.75% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 879.85%. This contributed to the annual value of $3.8 million for FY2024, which is 1832.76% up from last year.
  • Per International Stem Cell's latest filing, its Cost of Revenue stood at $1.0 million for Q3 2025, which was up 759.75% from $927000.0 recorded in Q2 2025.
  • In the past 5 years, International Stem Cell's Cost of Revenue registered a high of $1.1 million during Q4 2022, and its lowest value of $615000.0 during Q1 2021.
  • Its 5-year average for Cost of Revenue is $848157.9, with a median of $824000.0 in 2023.
  • Its Cost of Revenue has fluctuated over the past 5 years, first crashed by 2823.8% in 2021, then surged by 5455.78% in 2022.
  • Over the past 5 years, International Stem Cell's Cost of Revenue (Quarter) stood at $735000.0 in 2021, then surged by 54.56% to $1.1 million in 2022, then fell by 24.03% to $863000.0 in 2023, then grew by 14.72% to $990000.0 in 2024, then grew by 5.86% to $1.0 million in 2025.
  • Its Cost of Revenue was $1.0 million in Q3 2025, compared to $927000.0 in Q2 2025 and $992000.0 in Q1 2025.